IMS Health & Quintiles are now IQVIA™

A BETTER APPROACH TO RISK-BASED MONITORING

Execute confidently with IQVIA

THE SITUATION

Need to transform clinical development

10 years and $2.6B to develop a new drug[1]

- 100% SDV not optimal for the majority of trials
- Siloed data not ideal to minimize risk or maximize value

THE CHALLENGES

- Study protocol complexity
- Budget constraints
- Speed to market
- Change management
- Data integration complexity

THE NEED

An optimized clinical development model that uses data and analytics to reduce risk, while improving study quality and patient safety

THE SOLUTION

IQVIA™ Risk-Based Monitoring solution

REDUCING RISK AND COST

- Upfront and ongoing risk assessment
- Adaptive Centralized Monitoring model
- Increased study quality and management
- Faster, more informed decisions
- Reduced on-site visits
- Optimized resource allocation
- Predictive analytics identify potential risks

IMPROVING STUDY QUALITY

- Real-time data entry and site communication lowers error rate, reduces aged queries and missing pages
- Advanced analytics drive timely actions
- Medically trained staff protect study integrity
- Purpose-built Centralized Monitoring platform streamlines data review and oversight processes

ENHANCING SUBJECT SAFETY

- Predictive/advanced analytics identify/ resolve issues – at site and subject level
- Timely site communication and compliance
- Places focus on higher risk sites, data, events and subjects
- Medically trained staff perform subject-level data reviews to identify trends and ensure medical congruency

THE VALUE PROMISE

Execute your RBM trials with confidence by partnering with the RBM market leader to optimize your clinical trial

THE DIFFERENCE

EXPERIENCE More RBM studies underway delivering improved data quality, efficiency and enhanced patient safety

USAGE The RBM market leader as most used RBM provider[1,2]

SATISFACTION Delivering the highest level of RBM trial satisfaction in the market[2]

SPEED RBM studies reached database lock faster than non-RBM studies[3]

EFFICIENCY Lower error rate in critical data using RBM vs. traditional SDV

THERAPEUTIC EXPERTISE 14 Therapeutic Centers of Excellence

GLOBAL REACH 600+ central monitoring staff across 5 geographic regions

RBM TECHNOLOGY Proprietary Centralized Monitoring platform for improved efficiency and oversight

>300 RBM studies

>390,000 patients monitored

>39,000 sites supported

1. Tufts Center for the Study of Drug Development
2. ISR industry research report
3. Internal IQVIA data as of April 2019

CONTACT US

iqvia.com/contactus